Group 1 - The core viewpoint highlights the active trading and positive performance of the China A500 ETF Morgan and A500 Enhanced ETF Morgan, with the CSI A500 Index showing a slight increase of 0.14% as of 13:36 on May 23, 2025 [1] - Notable stocks within the CSI A500 Index include Siasun (601127) reaching a daily limit increase, Betta Pharmaceuticals (300558) rising by 12.02%, Huahai Pharmaceutical (600521) increasing by 8.47%, Tigermed (300347) up by 7.92%, and Xinlitai (002294) gaining 5.65% [1] Group 2 - Institutions emphasize the increasing asset allocation value in China, with "Opportunities in China amid Global Changes" becoming a significant topic in mid-term strategy outlooks [3] - The Chinese economy is showing steady improvement, supported by a combination of market stabilization policies that inject more certainty into the capital market, enhancing the attractiveness of Chinese assets [3] - Brokerages generally view Chinese assets as having both risk-hedging properties and long-term allocation value, positioning them as a "safe haven" for global funds [3] - Morgan Asset Management is focused on identifying relatively "certain" quality asset investment opportunities, launching the international "Dividend Toolbox" series of preferred funds to provide diversified dividend investment solutions for Chinese investors covering A-shares, Hong Kong stocks, and Asian markets [3]